Fluconazole Orally Dispersible Tablets for the Treatment of Patients with Oropharyngeal Candidiasis

1998 ◽  
Vol 26 (4) ◽  
pp. 209-218 ◽  
Author(s):  
B Vandercam ◽  
D Gibbs ◽  
M Valtonen ◽  
H Jäger ◽  
O Armignacco
Keyword(s):  
Signs And Symptoms ◽  
Oropharyngeal Candidiasis ◽  
Once Daily ◽  
Underlying Illness ◽  
Fluconazole Therapy ◽  
Aids Related Complex ◽  
Acquired Immunodeficiency ◽  
Dispersible Tablets ◽  
Immunodeficiency Syndrome

The efficacy and tolerability of fluconazole orally dispersible tablets (ODT) in the treatment of oropharyngeal candidiasis was evaluated in this multicentre non-comparative study. A total of 89 adults with signs and symptoms of oropharyngeal candidiasis were enrolled; 70 of whom completed therapy with fluconazole ODT 100 mg once daily for 7–14 days. Acquired immunodeficiency syndrome (AIDS)/ AIDS-related complex was an underlying illness in 69% of patients (61). An antimicrobial and corticosteroid therapy was given in 52% (46) and 20% (18) of patients, respectively. Of the 60 patients who had baseline signs and symptoms of infection and a culture positive for Candida albicans, 90% (54) were cured or had improved at the end of therapy, and the fungal pathogen was eradicated in 19/57 (33%) patients. At the 4-week post-treatment follow-up, signs and symptoms of oropharyngeal candidiasis were absent in 73% (27/37) patients. The adverse events and laboratory abnormalities recorded during the study period were attributable to underlying illnesses rather than to fluconazole therapy. These results indicate that this novel dosage form of fluconazole is effective and well tolerated in the treatment of oropharyngeal candidiasis.

Once-Daily Administration of 2′,3′-Dideoxyinosine (ddI) in Patients with the Acquired Immunodeficiency Syndrome or AIDS-Related Complex

1990 ◽  
Vol 322 (19) ◽  
pp. 1340-1345 ◽  
Author(s):  
Timothy P. Cooley ◽  
Laureen M. Kunches ◽  
Carol A. Saunders ◽  
Jitka K. Ritter ◽  
Christopher J. Perkins ◽  
...  
Keyword(s):  
Acquired Immunodeficiency Syndrome ◽  
Daily Administration ◽  
Once Daily ◽  
Aids Related Complex ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Related Complex

scholarly journals Overt Lower Gastrointestinal Bleeding and Pseudotumor: A Rare Presentation of Cytomegalovirus Infection

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Akanksha Agrawal ◽  
Deepanshu Jain ◽  
Sameer Siddique
Keyword(s):  
Highly Active Antiretroviral Therapy ◽  
The Body ◽  
Cmv Infection ◽  
Rare Presentation ◽  
Multiple Organs ◽  
Highly Active ◽  
History Of ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

Cytomegalovirus (CMV) is a ubiquitous organism which can infect multiple organs of the body. In an immunocompromised patient, it can have a myriad of gastrointestinal manifestations. We report a case of recurrent hematochezia and concomitant pseudotumor in an AIDS (acquired immunodeficiency syndrome) patient attributable to CMV infection. A 62-year-old man with a history of AIDS, noncompliant with highly active antiretroviral therapy (HAART), presented with bright red blood per rectum. Index colonoscopy showed presence of multiple ulcers, colonic stenosis, and mass-like appearing lesion. Biopsy confirmed CMV infection and ruled out malignancy. Cessation of dual antiplatelet therapy and compliance with HAART lead to clinical cessation of bleeding and endoscopic healing of ulcers with complete resolution of colon mass on follow-up colonoscopy.

scholarly journals Lack of evidence of prolonged human immunodeficiency virus infection before antibody seroconversion

Blood ◽  
1988 ◽  
Vol 71 (6) ◽  
pp. 1752-1754
Author(s):  
JE Groopman ◽  
T Caiazzo ◽  
MA Thomas ◽  
RA Ferriani ◽  
S Saltzman ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
High Risk ◽  
Screening Tests ◽  
Homosexual Men ◽  
Immunodeficiency Virus ◽  
Aids Related Complex ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Very High ◽  
Considerable Concern

Recently, considerable concern has been raised regarding the possibility that antibody-based screening tests for the human immunodeficiency virus (HIV) may fail to detect certain high-risk individuals for prolonged periods of time. It has been proposed that testing for HIV-related antigen may be a necessary procedure to detect such individuals. To address this issue, we longitudinally studied two groups of homosexual men: direct sexual partners of acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) patients and individuals who ultimately sero-converted. There was no evidence of prolonged infection with HIV in the absence of detectable antibody in these two groups. It appears at this time that, even among subjects at very high risk for HIV infection, currently available antibody-based assays are sufficient to identify infected individuals.

scholarly journals Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex

Blood ◽  
1991 ◽  
Vol 78 (12) ◽  
pp. 3148-3154 ◽  
Author(s):  
JD Levine ◽  
JD Allan ◽  
JH Tessitore ◽  
N Falcone ◽  
F Galasso ◽  
...  
Keyword(s):  
Full Dose ◽  
Gm Csf ◽  
Aids Related Complex ◽  
Group A ◽  
Acquired Immunodeficiency ◽  
Macrophage Colony Stimulating Factor ◽  
Macrophage Colony ◽  
Group B ◽  
Immunodeficiency Syndrome ◽  
Stimulating Factor

Abstract To evaluate the effect of recombinant granulocyte-macrophage colony- stimulating factor (GM-CSF) on patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were intolerant to zidovudine because of neutropenia, we performed a randomized, open- label study in which patients were assigned to one of two groups. Zidovudine was discontinued in group A patients before instituting GM- CSF treatment and was restarted in a graduated fashion over 4 weeks. Group B patients continued on full-dose (1,200 mg/d) zidovudine therapy while beginning GM-CSF therapy. A total of 17 patients were entered, eight in group A and nine in group B. Five of eight patients in group A and seven of nine in group B had a history of Pneumocystis carinii pneumonia (PCP). All were homosexual males, except one female in group A who was the sex partner of a bisexual male with AIDS. All patients had neutropenia (absolute neutrophil count [ANC] less than 1,000/microL) while taking full-dose zidovudine. The mean CD4 (+/- SD) lymphocyte level was 37 (+/- 29)/microL and 39 (+/- 44)/microL in groups A and B, respectively. After randomization, patients were begun on subcutaneous GM-CSF at a dose of 1.0 microgram/kg/d. Patients in group A received 2 weeks of daily GM-CSF, at which time zidovudine was restarted if the ANC was greater than 1,000/microL; if the ANC was less than 1,000/microL, the dose of GM-CSF was increased to 3.0 micrograms/kg, and at 2-week intervals either zidovudine was restarted or the dose of GM-CSF was increased to 5 micrograms/kg and then 10 micrograms/kg, to maintain the ANC greater than 1,000/microL. Group B patients received full-dose zidovudine concurrently with GM-CSF administration. The dose of GM-CSF was increased every 2 weeks if necessary to keep the ANC greater than 1,000/microL while maintaining full-dose zidovudine therapy. Patients in each group showed an increase in total white blood cell (WBC) count. Neutrophils and eosinophils were responsible for the majority of this increase. Patients in group A had a more rapid increase in WBC than those in group B; however, by week 8, the WBC in each group was essentially equal. Viral replication as measured by human immunodeficiency virus (HIV) p24 antigen (Ag) was decreased in four patients in each group, increased in one patient in each group, and remained unchanged in the remainder. The ability to culture virus from peripheral blood mononuclear cells was not changed by the regimen. The major toxicities of the regimen were fever and malaise.(ABSTRACT TRUNCATED AT 400 WORDS)

scholarly journals Risk of AIDS for recipients of blood components from donors who subsequently developed AIDS

Blood ◽  
1987 ◽  
Vol 70 (5) ◽  
pp. 1604-1610 ◽  
Author(s):  
HA Perkins ◽  
S Samson ◽  
J Garner ◽  
D Echenberg ◽  
JR Allen ◽  
...  
Keyword(s):  
San Francisco ◽  
Current Status ◽  
Time Interval ◽  
Blood Components ◽  
Aids Related Complex ◽  
Acquired Immunodeficiency ◽  
Almost All ◽  
Immunodeficiency Syndrome ◽  
Donated Blood ◽  
First Contact

Abstract Reported cases of acquired immunodeficiency syndrome (AIDS) in San Francisco as of March 31, 1986, include 92 individuals who had donated blood subsequent to 1978. Their donated blood components had been transfused into 406 different recipients. The current status of 336 of these recipients was ascertained as of April 1, 1986. Of these, 223 had died at the time of our first contact, almost all as a result of the condition for which they were transfused. Seven had developed AIDS; five of these died, two before entry into the study and three subsequently. Forty-six additional living recipients were interviewed and evaluated. Seven had the AIDS-related complex, 18 had antibody to the human immunodeficiency virus (HIV) but were otherwise healthy, and 19 had no detectable anti-HIV. Two had risk factors other than transfusion. The frequency of infection of the recipient decreased as the time interval between transfusion and the diagnosis of AIDS in the donor increased. This information should be useful when counseling patients who have been transfused with blood components from donors later found to be infected with HIV.

scholarly journals Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice

Blood ◽  
1990 ◽  
Vol 76 (11) ◽  
pp. 2216-2221 ◽  
Author(s):  
A Falcone ◽  
JW Darnowski ◽  
RM Ruprecht ◽  
SH Chu ◽  
I Brunetti ◽  
...  
Keyword(s):  
Leukemia Virus ◽  
Hematologic Toxicity ◽  
Therapeutic Effects ◽  
Dependent Manner ◽  
Aids Related Complex ◽  
Effective Doses ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Oral Doses

Abstract It has been reported that in vitro uridine (Urd) can reverse azidothymidine (AZT) cytotoxicity without decreasing anti-human immunodeficiency virus (HIV) activity. Our studies in mice have shown that daily oral doses of benzylacyclouridine (BAU), an inhibitor of Urd breakdown, also reduces AZT hematologic toxicity, presumably by elevating the plasma concentration of Urd. We now extend these murine studies and report the effect of various doses of exogenous Urd, various doses of BAU, or the combination of BAU and Urd, administered daily, on AZT-induced toxicity. In mice receiving concomitant AZT, daily doses of Urd of 1,000 to 2,000 mg/kg increase peripheral reticulocytes and slightly reduce AZT-induced hematologic toxicity. However, the range of effective doses is narrow, and higher doses of Urd (greater than 3,000 mg/kg/d) significantly enhance hematologic toxicity. At its most effective dose, (2,000 mg/kg/d), Urd produces 28% mortality. In contrast, BAU doses up to 300 mg/kg/d reduced AZT-related hematologic toxicity in a dose-dependent manner without mortality. Higher daily doses of BAU and the combination of BAU with low doses of Urd were not more effective. Studies conducted in mice infected with the Rauscher murine leukemia virus (RLV) indicate that BAU does not impair the antiretroviral effect of AZT when administered at doses that reduce AZT-induced anemia and leukopenia. These findings may be significant for the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Sign in / Sign up

Export Citation Format

Share Document